The Efficacy and Cognitive Impact of Perampanel Monotherapy in Patients with Self-Limited Epilepsy with Centrotemporal Spikes: A Retrospective Analysis

Figures & data

Table 1 General Information of the Patients ()

	SeLECTS (N=86)
Gander
Male	44% (38/86)
Female	56% (48/86)
Weight (Kg)
<20	34% (29/86)
20–30	40% (34/86)
>30	26% (23/86)
Age (years)
6–11	98% (84/86)
≥12	2% (2/86)
Onset age	5.4–11.5
Average age	8.62 ± 2.03
Number of seizures	2–7
Average number of seizures	2.94 ± 4.17
Seizure Type
FOS	63% (54/86)
FBTCS	37% (32/86)
Seizure duration	20 s - 10 min
Seizure time
Status epilepticus	1% (1/86)
Waking phase	5% (4/86)
Sleep phase	82% (71/86)
Waking phase and sleep phase	12% (10/86)
Formerly medical history
History of birth asphyxia	1% (1/86)
History of febrile seizures	16% (14/86)
Family history of febrile seizures	36% (5/14)
Family history of epilepsy	2% (3/86)
Localization of EEG characteristic spikes
Central and temporal areas	53% (46/86)
Frontal area	33% (28/86)
Parietal area	14% (12/86)

Note: “” means “mean ± standard deviation”.

Table 2 The Efficacy and Drug Retention Rate of PER Monotherapy

Therapy Time	Seizure Frequency	Effective (%)	Seizure-Free (%)	Drug Retention Rate (%)
3 months	Once / a month	98.83% (85/86)	97.6% (84/86)	98.83%
6 months	Once / 3 months	86.04% (74/86)	81.39% (70/86)	98.83%
12 months	Once / 6 months	84.89% (73/86)	79.07% (68/86)	98.83%

Table 3 Drug Use and Adverse Reactions at 12 Months of Treatment

Groups	Number of Initial Drug Users (n)	Initial Dose (mg/Day)	Maintenance Dose (mg/Day, n)	Incidence Rate of Adverse Reactions (%)	Drug Retention Rate (%)
<20 (Kg)	29	0.5	2 (26)	0	100
			4 (3)
20–30 (Kg)	34	1	2 (24)	2 (5.88%)	98.83%
			4 (10)
>30 (Kg)	23	2	2 (20)	6 (26.08%)	100%
			4 (3)

Table 4 Analysis of ERP P300 and WISC-IV Results After 12 Months of PER Treatment

Test	Total Number (n)	Before Treatment M (95%)	After Treatment M (95%)	P
ERP P300
P300 latency (ms)	86	362.00 (361.98, 368.02)	365.00 (362.75, 369.37)	0.690
P300 amplitude (uv)	86	11.45 (11.16, 11.54)	11.34 (11.13, 11.54)	0.710
WISC-IV
VCI (score)	86	84.00 (84.60, 84.91)	85.00 (84.87, 86.89)	0.95
PRI (score)	86	85.00 (84.50, 86.16)	85.00 (84.48, 86.24)	0.837
WMI (score)	86	85.00 (84.51, 86.27)	84.00 (84.34, 86.01)	0.580
PSI (score)	86	84.00 (83.82, 85.73)	85.00 (84.05, 85.85)	0.550
FSIQ (score)	86	85.00 (84.77, 86.03)	85.00 (84.83, 86.01)	0.960

Notes: “M (95%)” means “median (95% confidence interval)”; before and after treatment, p>0.05.

Abbreviations: VCI, speech comprehension index; PRI, perceptual reasoning index; WMI, working memory index; PSI, processing speed index; FSIQ, total IQ.

Table 5 Correlation Analysis Between WISC-IV Scores and Seizure Frequency Before and After 12 Months of per Treatment

Group	Seizure Frequency M (95%)	FSIQ (Score) M (95%)	Correlation Coefficient	P
Before treatment	4.00 (3.50, 4.03)	85 (84.77, 86.03)	0.009	0.935
After treatment	0.00 (0.16, 0.43	85 (84.83, 86.01)	−0.19	0.865
Difference before and after treatment	−3 (−3.69, −3.00)	0.00 (−0.23, 0.24)	0.004	0.968

Notes: “M (95%)” means “median (95% confidence interval)”; Difference before and after treatment=After treatment-Before treatment.